Daré Bioscience Reports Revenue Growth in Q2 2026 Amid Ongoing Losses

Daré Bioscience, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $187,546, a significant increase from a loss of $21,172 in the same period of the previous year. For the first half of 2026, the company generated $340,001 in revenue, compared to just $4,255 in the first half of 2025. This growth is attributed primarily to research and development services and royalty revenue from agreements with the Gates Foundation, which commenced in late 2025. However, the company continues to face challenges, with a net loss of $2,982,773 for the quarter and $5,982,662 for the six months ended June 30, 2026, reflecting a reduction in losses compared to the previous year.

In terms of operational changes, Daré has shifted its business model to include a dual-path approach for product commercialization, pursuing both traditional FDA approval and earlier market access through Section 503B compounding. This strategy aims to expedite the availability of its products, including the recently launched consumer health product, Flora Sync LF5, which became available in June 2026. The company is also advancing its clinical programs, including the pivotal Phase 3 study of Ovaprene, which is supported by non-dilutive grant funding.

The company’s financial position has seen a decline, with cash and cash equivalents decreasing to approximately $12.6 million as of June 30, 2026, down from $24.7 million at the end of 2025. Current liabilities also decreased to $16.9 million from $23.7 million, primarily due to a reduction in deferred grant funding. Despite these changes, Daré reported a working capital deficit of approximately $0.2 million, raising concerns about its ability to continue operations without additional capital.

Looking ahead, Daré Bioscience anticipates that its existing cash reserves will support operations through the fourth quarter of 2026, but acknowledges the need for further capital to fund ongoing development and commercialization efforts. The company is exploring various financing options, including equity sales and collaborations, to bolster its financial position. However, there is substantial doubt about its ability to continue as a going concern within the next twelve months, given the uncertainty surrounding future revenue generation and the potential need to scale back or eliminate product candidate programs if additional funding is not secured.